

Global Biosimilars and Innovative Biological Drugs Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/GCCACE01D28FEN.html>

Date: October 2024

Pages: 159

Price: US\$ 3,200.00 (Single User License)

ID: GCCACE01D28FEN

Abstracts

Report Overview

Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products. A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original 'innovator' products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.

The global Biosimilars and Innovative Biological Drugs market size was estimated at USD 409000 million in 2023 and is projected to reach USD 866541.18 million by 2032, exhibiting a CAGR of 8.70% during the forecast period.

North America Biosimilars and Innovative Biological Drugs market size was estimated at USD 123061.07 million in 2023, at a CAGR of 7.46% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Biosimilars and Innovative Biological Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Biosimilars and Innovative Biological Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Biosimilars and Innovative Biological Drugs market in any manner.

Global Biosimilars and Innovative Biological Drugs Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Roche

Amgen

AbbVie

Sanofi

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

Biogen

Celltrion

Sobi

3SBIO

Changchun High Tech

Kanghong Pharma

Innovent Biologics

Gan&Lee

Tonghua Dongbao

United Laboratory

Market Segmentation (by Type)

Monoclonal Antibodies

Interferon

Insulin

Vaccines

Others

Market Segmentation (by Application)

Hospital

Retail Pharmacy

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Biosimilars and Innovative Biological Drugs Market

Overview of the regional outlook of the Biosimilars and Innovative Biological Drugs Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Biosimilars and Innovative Biological Drugs Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types,

covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Biosimilars and Innovative Biological Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Biosimilars and Innovative Biological Drugs

1.2 Key Market Segments

1.2.1 Biosimilars and Innovative Biological Drugs Segment by Type

1.2.2 Biosimilars and Innovative Biological Drugs Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 BIOSIMILARS AND INNOVATIVE BIOLOGICAL DRUGS MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Biosimilars and Innovative Biological Drugs Market Size (M USD) Estimates and Forecasts (2019-2032)

2.1.2 Global Biosimilars and Innovative Biological Drugs Sales Estimates and Forecasts (2019-2032)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 BIOSIMILARS AND INNOVATIVE BIOLOGICAL DRUGS MARKET COMPETITIVE LANDSCAPE

3.1 Global Biosimilars and Innovative Biological Drugs Sales by Manufacturers (2019-2024)

3.2 Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Manufacturers (2019-2024)

3.3 Biosimilars and Innovative Biological Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Biosimilars and Innovative Biological Drugs Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Biosimilars and Innovative Biological Drugs Sales Sites, Area Served, Product Type

3.6 Biosimilars and Innovative Biological Drugs Market Competitive Situation and Trends

3.6.1 Biosimilars and Innovative Biological Drugs Market Concentration Rate

3.6.2 Global 5 and 10 Largest Biosimilars and Innovative Biological Drugs Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 BIOSIMILARS AND INNOVATIVE BIOLOGICAL DRUGS INDUSTRY CHAIN ANALYSIS

4.1 Biosimilars and Innovative Biological Drugs Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF BIOSIMILARS AND INNOVATIVE BIOLOGICAL DRUGS MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 BIOSIMILARS AND INNOVATIVE BIOLOGICAL DRUGS MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Biosimilars and Innovative Biological Drugs Sales Market Share by Type (2019-2024)

6.3 Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)

6.4 Global Biosimilars and Innovative Biological Drugs Price by Type (2019-2024)

7 BIOSIMILARS AND INNOVATIVE BIOLOGICAL DRUGS MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Biosimilars and Innovative Biological Drugs Market Sales by Application (2019-2024)
- 7.3 Global Biosimilars and Innovative Biological Drugs Market Size (M USD) by Application (2019-2024)
- 7.4 Global Biosimilars and Innovative Biological Drugs Sales Growth Rate by Application (2019-2024)

8 BIOSIMILARS AND INNOVATIVE BIOLOGICAL DRUGS MARKET CONSUMPTION BY REGION

- 8.1 Global Biosimilars and Innovative Biological Drugs Sales by Region
 - 8.1.1 Global Biosimilars and Innovative Biological Drugs Sales by Region
 - 8.1.2 Global Biosimilars and Innovative Biological Drugs Sales Market Share by Region
- 8.2 North America
 - 8.2.1 North America Biosimilars and Innovative Biological Drugs Sales by Country
 - 8.2.2 U.S.
 - 8.2.3 Canada
 - 8.2.4 Mexico
- 8.3 Europe
 - 8.3.1 Europe Biosimilars and Innovative Biological Drugs Sales by Country
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 U.K.
 - 8.3.5 Italy
 - 8.3.6 Russia
- 8.4 Asia Pacific
 - 8.4.1 Asia Pacific Biosimilars and Innovative Biological Drugs Sales by Region
 - 8.4.2 China
 - 8.4.3 Japan
 - 8.4.4 South Korea
 - 8.4.5 India
 - 8.4.6 Southeast Asia
- 8.5 South America
 - 8.5.1 South America Biosimilars and Innovative Biological Drugs Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Biosimilars and Innovative Biological Drugs Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 BIOSIMILARS AND INNOVATIVE BIOLOGICAL DRUGS MARKET PRODUCTION BY REGION

9.1 Global Production of Biosimilars and Innovative Biological Drugs by Region (2019-2024)

9.2 Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Region (2019-2024)

9.3 Global Biosimilars and Innovative Biological Drugs Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Biosimilars and Innovative Biological Drugs Production

9.4.1 North America Biosimilars and Innovative Biological Drugs Production Growth Rate (2019-2024)

9.4.2 North America Biosimilars and Innovative Biological Drugs Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Biosimilars and Innovative Biological Drugs Production

9.5.1 Europe Biosimilars and Innovative Biological Drugs Production Growth Rate (2019-2024)

9.5.2 Europe Biosimilars and Innovative Biological Drugs Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Biosimilars and Innovative Biological Drugs Production (2019-2024)

9.6.1 Japan Biosimilars and Innovative Biological Drugs Production Growth Rate (2019-2024)

9.6.2 Japan Biosimilars and Innovative Biological Drugs Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Biosimilars and Innovative Biological Drugs Production (2019-2024)

9.7.1 China Biosimilars and Innovative Biological Drugs Production Growth Rate (2019-2024)

9.7.2 China Biosimilars and Innovative Biological Drugs Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

10.1 Roche

- 10.1.1 Roche Biosimilars and Innovative Biological Drugs Basic Information
- 10.1.2 Roche Biosimilars and Innovative Biological Drugs Product Overview
- 10.1.3 Roche Biosimilars and Innovative Biological Drugs Product Market Performance
- 10.1.4 Roche Business Overview
- 10.1.5 Roche Biosimilars and Innovative Biological Drugs SWOT Analysis
- 10.1.6 Roche Recent Developments

10.2 Amgen

- 10.2.1 Amgen Biosimilars and Innovative Biological Drugs Basic Information
- 10.2.2 Amgen Biosimilars and Innovative Biological Drugs Product Overview
- 10.2.3 Amgen Biosimilars and Innovative Biological Drugs Product Market Performance
- 10.2.4 Amgen Business Overview
- 10.2.5 Amgen Biosimilars and Innovative Biological Drugs SWOT Analysis
- 10.2.6 Amgen Recent Developments

10.3 AbbVie

- 10.3.1 AbbVie Biosimilars and Innovative Biological Drugs Basic Information
- 10.3.2 AbbVie Biosimilars and Innovative Biological Drugs Product Overview
- 10.3.3 AbbVie Biosimilars and Innovative Biological Drugs Product Market Performance
- 10.3.4 AbbVie Biosimilars and Innovative Biological Drugs SWOT Analysis
- 10.3.5 AbbVie Business Overview
- 10.3.6 AbbVie Recent Developments

10.4 Sanofi

- 10.4.1 Sanofi Biosimilars and Innovative Biological Drugs Basic Information
- 10.4.2 Sanofi Biosimilars and Innovative Biological Drugs Product Overview
- 10.4.3 Sanofi Biosimilars and Innovative Biological Drugs Product Market Performance
- 10.4.4 Sanofi Business Overview
- 10.4.5 Sanofi Recent Developments

10.5 Johnson and Johnson

- 10.5.1 Johnson and Johnson Biosimilars and Innovative Biological Drugs Basic Information
- 10.5.2 Johnson and Johnson Biosimilars and Innovative Biological Drugs Product Overview

10.5.3 Johnson and Johnson Biosimilars and Innovative Biological Drugs Product Market Performance

10.5.4 Johnson and Johnson Business Overview

10.5.5 Johnson and Johnson Recent Developments

10.6 Pfizer

10.6.1 Pfizer Biosimilars and Innovative Biological Drugs Basic Information

10.6.2 Pfizer Biosimilars and Innovative Biological Drugs Product Overview

10.6.3 Pfizer Biosimilars and Innovative Biological Drugs Product Market Performance

10.6.4 Pfizer Business Overview

10.6.5 Pfizer Recent Developments

10.7 Novo Nordisk

10.7.1 Novo Nordisk Biosimilars and Innovative Biological Drugs Basic Information

10.7.2 Novo Nordisk Biosimilars and Innovative Biological Drugs Product Overview

10.7.3 Novo Nordisk Biosimilars and Innovative Biological Drugs Product Market Performance

10.7.4 Novo Nordisk Business Overview

10.7.5 Novo Nordisk Recent Developments

10.8 Eli Lilly

10.8.1 Eli Lilly Biosimilars and Innovative Biological Drugs Basic Information

10.8.2 Eli Lilly Biosimilars and Innovative Biological Drugs Product Overview

10.8.3 Eli Lilly Biosimilars and Innovative Biological Drugs Product Market Performance

10.8.4 Eli Lilly Business Overview

10.8.5 Eli Lilly Recent Developments

10.9 Novartis

10.9.1 Novartis Biosimilars and Innovative Biological Drugs Basic Information

10.9.2 Novartis Biosimilars and Innovative Biological Drugs Product Overview

10.9.3 Novartis Biosimilars and Innovative Biological Drugs Product Market Performance

10.9.4 Novartis Business Overview

10.9.5 Novartis Recent Developments

10.10 Merck

10.10.1 Merck Biosimilars and Innovative Biological Drugs Basic Information

10.10.2 Merck Biosimilars and Innovative Biological Drugs Product Overview

10.10.3 Merck Biosimilars and Innovative Biological Drugs Product Market Performance

10.10.4 Merck Business Overview

10.10.5 Merck Recent Developments

10.11 Biogen

- 10.11.1 Biogen Biosimilars and Innovative Biological Drugs Basic Information
- 10.11.2 Biogen Biosimilars and Innovative Biological Drugs Product Overview
- 10.11.3 Biogen Biosimilars and Innovative Biological Drugs Product Market Performance
- 10.11.4 Biogen Business Overview
- 10.11.5 Biogen Recent Developments
- 10.12 Celltrion
 - 10.12.1 Celltrion Biosimilars and Innovative Biological Drugs Basic Information
 - 10.12.2 Celltrion Biosimilars and Innovative Biological Drugs Product Overview
 - 10.12.3 Celltrion Biosimilars and Innovative Biological Drugs Product Market Performance
 - 10.12.4 Celltrion Business Overview
 - 10.12.5 Celltrion Recent Developments
- 10.13 Sobi
 - 10.13.1 Sobi Biosimilars and Innovative Biological Drugs Basic Information
 - 10.13.2 Sobi Biosimilars and Innovative Biological Drugs Product Overview
 - 10.13.3 Sobi Biosimilars and Innovative Biological Drugs Product Market Performance
 - 10.13.4 Sobi Business Overview
 - 10.13.5 Sobi Recent Developments
- 10.14 3SBIO
 - 10.14.1 3SBIO Biosimilars and Innovative Biological Drugs Basic Information
 - 10.14.2 3SBIO Biosimilars and Innovative Biological Drugs Product Overview
 - 10.14.3 3SBIO Biosimilars and Innovative Biological Drugs Product Market Performance
 - 10.14.4 3SBIO Business Overview
 - 10.14.5 3SBIO Recent Developments
- 10.15 Changchun High Tech
 - 10.15.1 Changchun High Tech Biosimilars and Innovative Biological Drugs Basic Information
 - 10.15.2 Changchun High Tech Biosimilars and Innovative Biological Drugs Product Overview
 - 10.15.3 Changchun High Tech Biosimilars and Innovative Biological Drugs Product Market Performance
 - 10.15.4 Changchun High Tech Business Overview
 - 10.15.5 Changchun High Tech Recent Developments
- 10.16 Kanghong Pharma
 - 10.16.1 Kanghong Pharma Biosimilars and Innovative Biological Drugs Basic Information
 - 10.16.2 Kanghong Pharma Biosimilars and Innovative Biological Drugs Product

Overview

10.16.3 Kanghong Pharma Biosimilars and Innovative Biological Drugs Product Market Performance

10.16.4 Kanghong Pharma Business Overview

10.16.5 Kanghong Pharma Recent Developments

10.17 Innovent Biologics

10.17.1 Innovent Biologics Biosimilars and Innovative Biological Drugs Basic Information

10.17.2 Innovent Biologics Biosimilars and Innovative Biological Drugs Product Overview

10.17.3 Innovent Biologics Biosimilars and Innovative Biological Drugs Product Market Performance

10.17.4 Innovent Biologics Business Overview

10.17.5 Innovent Biologics Recent Developments

10.18 GanandLee

10.18.1 GanandLee Biosimilars and Innovative Biological Drugs Basic Information

10.18.2 GanandLee Biosimilars and Innovative Biological Drugs Product Overview

10.18.3 GanandLee Biosimilars and Innovative Biological Drugs Product Market Performance

10.18.4 GanandLee Business Overview

10.18.5 GanandLee Recent Developments

10.19 Tonghua Dongbao

10.19.1 Tonghua Dongbao Biosimilars and Innovative Biological Drugs Basic Information

10.19.2 Tonghua Dongbao Biosimilars and Innovative Biological Drugs Product Overview

10.19.3 Tonghua Dongbao Biosimilars and Innovative Biological Drugs Product Market Performance

10.19.4 Tonghua Dongbao Business Overview

10.19.5 Tonghua Dongbao Recent Developments

10.20 United Laboratory

10.20.1 United Laboratory Biosimilars and Innovative Biological Drugs Basic Information

10.20.2 United Laboratory Biosimilars and Innovative Biological Drugs Product Overview

10.20.3 United Laboratory Biosimilars and Innovative Biological Drugs Product Market Performance

10.20.4 United Laboratory Business Overview

10.20.5 United Laboratory Recent Developments

11 BIOSIMILARS AND INNOVATIVE BIOLOGICAL DRUGS MARKET FORECAST BY REGION

11.1 Global Biosimilars and Innovative Biological Drugs Market Size Forecast

11.2 Global Biosimilars and Innovative Biological Drugs Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe Biosimilars and Innovative Biological Drugs Market Size Forecast by Country

11.2.3 Asia Pacific Biosimilars and Innovative Biological Drugs Market Size Forecast by Region

11.2.4 South America Biosimilars and Innovative Biological Drugs Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Consumption of Biosimilars and Innovative Biological Drugs by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

12.1 Global Biosimilars and Innovative Biological Drugs Market Forecast by Type (2025-2032)

12.1.1 Global Forecasted Sales of Biosimilars and Innovative Biological Drugs by Type (2025-2032)

12.1.2 Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Type (2025-2032)

12.1.3 Global Forecasted Price of Biosimilars and Innovative Biological Drugs by Type (2025-2032)

12.2 Global Biosimilars and Innovative Biological Drugs Market Forecast by Application (2025-2032)

12.2.1 Global Biosimilars and Innovative Biological Drugs Sales (K MT) Forecast by Application

12.2.2 Global Biosimilars and Innovative Biological Drugs Market Size (M USD) Forecast by Application (2025-2032)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Biosimilars and Innovative Biological Drugs Market Size Comparison by Region (M USD)

Table 5. Global Biosimilars and Innovative Biological Drugs Sales (K MT) by Manufacturers (2019-2024)

Table 6. Global Biosimilars and Innovative Biological Drugs Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Biosimilars and Innovative Biological Drugs Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Biosimilars and Innovative Biological Drugs Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars and Innovative Biological Drugs as of 2022)

Table 10. Global Market Biosimilars and Innovative Biological Drugs Average Price (USD/MT) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Biosimilars and Innovative Biological Drugs Sales Sites and Area Served

Table 12. Manufacturers Biosimilars and Innovative Biological Drugs Product Type

Table 13. Global Biosimilars and Innovative Biological Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Biosimilars and Innovative Biological Drugs

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Biosimilars and Innovative Biological Drugs Market Challenges

Table 22. Global Biosimilars and Innovative Biological Drugs Sales by Type (K MT)

Table 23. Global Biosimilars and Innovative Biological Drugs Market Size by Type (M USD)

Table 24. Global Biosimilars and Innovative Biological Drugs Sales (K MT) by Type (2019-2024)

Table 25. Global Biosimilars and Innovative Biological Drugs Sales Market Share by Type (2019-2024)

Table 26. Global Biosimilars and Innovative Biological Drugs Market Size (M USD) by Type (2019-2024)

Table 27. Global Biosimilars and Innovative Biological Drugs Market Size Share by Type (2019-2024)

Table 28. Global Biosimilars and Innovative Biological Drugs Price (USD/MT) by Type (2019-2024)

Table 29. Global Biosimilars and Innovative Biological Drugs Sales (K MT) by Application

Table 30. Global Biosimilars and Innovative Biological Drugs Market Size by Application

Table 31. Global Biosimilars and Innovative Biological Drugs Sales by Application (2019-2024) & (K MT)

Table 32. Global Biosimilars and Innovative Biological Drugs Sales Market Share by Application (2019-2024)

Table 33. Global Biosimilars and Innovative Biological Drugs Sales by Application (2019-2024) & (M USD)

Table 34. Global Biosimilars and Innovative Biological Drugs Market Share by Application (2019-2024)

Table 35. Global Biosimilars and Innovative Biological Drugs Sales Growth Rate by Application (2019-2024)

Table 36. Global Biosimilars and Innovative Biological Drugs Sales by Region (2019-2024) & (K MT)

Table 37. Global Biosimilars and Innovative Biological Drugs Sales Market Share by Region (2019-2024)

Table 38. North America Biosimilars and Innovative Biological Drugs Sales by Country (2019-2024) & (K MT)

Table 39. Europe Biosimilars and Innovative Biological Drugs Sales by Country (2019-2024) & (K MT)

Table 40. Asia Pacific Biosimilars and Innovative Biological Drugs Sales by Region (2019-2024) & (K MT)

Table 41. South America Biosimilars and Innovative Biological Drugs Sales by Country (2019-2024) & (K MT)

Table 42. Middle East and Africa Biosimilars and Innovative Biological Drugs Sales by Region (2019-2024) & (K MT)

Table 43. Global Biosimilars and Innovative Biological Drugs Production (K MT) by Region (2019-2024)

Table 44. Global Biosimilars and Innovative Biological Drugs Revenue (US\$ Million) by Region (2019-2024)

Table 45. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Region (2019-2024)

Table 46. Global Biosimilars and Innovative Biological Drugs Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 47. North America Biosimilars and Innovative Biological Drugs Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 48. Europe Biosimilars and Innovative Biological Drugs Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 49. Japan Biosimilars and Innovative Biological Drugs Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 50. China Biosimilars and Innovative Biological Drugs Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 51. Roche Biosimilars and Innovative Biological Drugs Basic Information

Table 52. Roche Biosimilars and Innovative Biological Drugs Product Overview

Table 53. Roche Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 54. Roche Business Overview

Table 55. Roche Biosimilars and Innovative Biological Drugs SWOT Analysis

Table 56. Roche Recent Developments

Table 57. Amgen Biosimilars and Innovative Biological Drugs Basic Information

Table 58. Amgen Biosimilars and Innovative Biological Drugs Product Overview

Table 59. Amgen Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 60. Amgen Business Overview

Table 61. Amgen Biosimilars and Innovative Biological Drugs SWOT Analysis

Table 62. Amgen Recent Developments

Table 63. AbbVie Biosimilars and Innovative Biological Drugs Basic Information

Table 64. AbbVie Biosimilars and Innovative Biological Drugs Product Overview

Table 65. AbbVie Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 66. AbbVie Biosimilars and Innovative Biological Drugs SWOT Analysis

Table 67. AbbVie Business Overview

Table 68. AbbVie Recent Developments

Table 69. Sanofi Biosimilars and Innovative Biological Drugs Basic Information

Table 70. Sanofi Biosimilars and Innovative Biological Drugs Product Overview

Table 71. Sanofi Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 72. Sanofi Business Overview

Table 73. Sanofi Recent Developments

Table 74. Johnson and Johnson Biosimilars and Innovative Biological Drugs Basic Information

Table 75. Johnson and Johnson Biosimilars and Innovative Biological Drugs Product Overview

Table 76. Johnson and Johnson Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 77. Johnson and Johnson Business Overview

Table 78. Johnson and Johnson Recent Developments

Table 79. Pfizer Biosimilars and Innovative Biological Drugs Basic Information

Table 80. Pfizer Biosimilars and Innovative Biological Drugs Product Overview

Table 81. Pfizer Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 82. Pfizer Business Overview

Table 83. Pfizer Recent Developments

Table 84. Novo Nordisk Biosimilars and Innovative Biological Drugs Basic Information

Table 85. Novo Nordisk Biosimilars and Innovative Biological Drugs Product Overview

Table 86. Novo Nordisk Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 87. Novo Nordisk Business Overview

Table 88. Novo Nordisk Recent Developments

Table 89. Eli Lilly Biosimilars and Innovative Biological Drugs Basic Information

Table 90. Eli Lilly Biosimilars and Innovative Biological Drugs Product Overview

Table 91. Eli Lilly Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 92. Eli Lilly Business Overview

Table 93. Eli Lilly Recent Developments

Table 94. Novartis Biosimilars and Innovative Biological Drugs Basic Information

Table 95. Novartis Biosimilars and Innovative Biological Drugs Product Overview

Table 96. Novartis Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 97. Novartis Business Overview

Table 98. Novartis Recent Developments

Table 99. Merck Biosimilars and Innovative Biological Drugs Basic Information

Table 100. Merck Biosimilars and Innovative Biological Drugs Product Overview

Table 101. Merck Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 102. Merck Business Overview

Table 103. Merck Recent Developments

Table 104. Biogen Biosimilars and Innovative Biological Drugs Basic Information

Table 105. Biogen Biosimilars and Innovative Biological Drugs Product Overview
Table 106. Biogen Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. Biogen Business Overview
Table 108. Biogen Recent Developments
Table 109. Celltrion Biosimilars and Innovative Biological Drugs Basic Information
Table 110. Celltrion Biosimilars and Innovative Biological Drugs Product Overview
Table 111. Celltrion Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 112. Celltrion Business Overview
Table 113. Celltrion Recent Developments
Table 114. Sobi Biosimilars and Innovative Biological Drugs Basic Information
Table 115. Sobi Biosimilars and Innovative Biological Drugs Product Overview
Table 116. Sobi Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 117. Sobi Business Overview
Table 118. Sobi Recent Developments
Table 119. 3SBIO Biosimilars and Innovative Biological Drugs Basic Information
Table 120. 3SBIO Biosimilars and Innovative Biological Drugs Product Overview
Table 121. 3SBIO Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 122. 3SBIO Business Overview
Table 123. 3SBIO Recent Developments
Table 124. Changchun High Tech Biosimilars and Innovative Biological Drugs Basic Information
Table 125. Changchun High Tech Biosimilars and Innovative Biological Drugs Product Overview
Table 126. Changchun High Tech Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 127. Changchun High Tech Business Overview
Table 128. Changchun High Tech Recent Developments
Table 129. Kanghong Pharma Biosimilars and Innovative Biological Drugs Basic Information
Table 130. Kanghong Pharma Biosimilars and Innovative Biological Drugs Product Overview
Table 131. Kanghong Pharma Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 132. Kanghong Pharma Business Overview
Table 133. Kanghong Pharma Recent Developments

Table 134. Innovent Biologics Biosimilars and Innovative Biological Drugs Basic Information

Table 135. Innovent Biologics Biosimilars and Innovative Biological Drugs Product Overview

Table 136. Innovent Biologics Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 137. Innovent Biologics Business Overview

Table 138. Innovent Biologics Recent Developments

Table 139. GanandLee Biosimilars and Innovative Biological Drugs Basic Information

Table 140. GanandLee Biosimilars and Innovative Biological Drugs Product Overview

Table 141. GanandLee Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 142. GanandLee Business Overview

Table 143. GanandLee Recent Developments

Table 144. Tonghua Dongbao Biosimilars and Innovative Biological Drugs Basic Information

Table 145. Tonghua Dongbao Biosimilars and Innovative Biological Drugs Product Overview

Table 146. Tonghua Dongbao Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 147. Tonghua Dongbao Business Overview

Table 148. Tonghua Dongbao Recent Developments

Table 149. United Laboratory Biosimilars and Innovative Biological Drugs Basic Information

Table 150. United Laboratory Biosimilars and Innovative Biological Drugs Product Overview

Table 151. United Laboratory Biosimilars and Innovative Biological Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 152. United Laboratory Business Overview

Table 153. United Laboratory Recent Developments

Table 154. Global Biosimilars and Innovative Biological Drugs Sales Forecast by Region (2025-2032) & (K MT)

Table 155. Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Region (2025-2032) & (M USD)

Table 156. North America Biosimilars and Innovative Biological Drugs Sales Forecast by Country (2025-2032) & (K MT)

Table 157. North America Biosimilars and Innovative Biological Drugs Market Size Forecast by Country (2025-2032) & (M USD)

Table 158. Europe Biosimilars and Innovative Biological Drugs Sales Forecast by

Country (2025-2032) & (K MT)

Table 159. Europe Biosimilars and Innovative Biological Drugs Market Size Forecast by Country (2025-2032) & (M USD)

Table 160. Asia Pacific Biosimilars and Innovative Biological Drugs Sales Forecast by Region (2025-2032) & (K MT)

Table 161. Asia Pacific Biosimilars and Innovative Biological Drugs Market Size Forecast by Region (2025-2032) & (M USD)

Table 162. South America Biosimilars and Innovative Biological Drugs Sales Forecast by Country (2025-2032) & (K MT)

Table 163. South America Biosimilars and Innovative Biological Drugs Market Size Forecast by Country (2025-2032) & (M USD)

Table 164. Middle East and Africa Biosimilars and Innovative Biological Drugs Consumption Forecast by Country (2025-2032) & (Units)

Table 165. Middle East and Africa Biosimilars and Innovative Biological Drugs Market Size Forecast by Country (2025-2032) & (M USD)

Table 166. Global Biosimilars and Innovative Biological Drugs Sales Forecast by Type (2025-2032) & (K MT)

Table 167. Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Type (2025-2032) & (M USD)

Table 168. Global Biosimilars and Innovative Biological Drugs Price Forecast by Type (2025-2032) & (USD/MT)

Table 169. Global Biosimilars and Innovative Biological Drugs Sales (K MT) Forecast by Application (2025-2032)

Table 170. Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Application (2025-2032) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Biosimilars and Innovative Biological Drugs

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Biosimilars and Innovative Biological Drugs Market Size (M USD), 2019-2032

Figure 5. Global Biosimilars and Innovative Biological Drugs Market Size (M USD) (2019-2032)

Figure 6. Global Biosimilars and Innovative Biological Drugs Sales (K MT) & (2019-2032)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Biosimilars and Innovative Biological Drugs Market Size by Country (M USD)

Figure 11. Biosimilars and Innovative Biological Drugs Sales Share by Manufacturers in 2023

Figure 12. Global Biosimilars and Innovative Biological Drugs Revenue Share by Manufacturers in 2023

Figure 13. Biosimilars and Innovative Biological Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Biosimilars and Innovative Biological Drugs Average Price (USD/MT) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Biosimilars and Innovative Biological Drugs Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Biosimilars and Innovative Biological Drugs Market Share by Type

Figure 18. Sales Market Share of Biosimilars and Innovative Biological Drugs by Type (2019-2024)

Figure 19. Sales Market Share of Biosimilars and Innovative Biological Drugs by Type in 2023

Figure 20. Market Size Share of Biosimilars and Innovative Biological Drugs by Type (2019-2024)

Figure 21. Market Size Market Share of Biosimilars and Innovative Biological Drugs by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Biosimilars and Innovative Biological Drugs Market Share by

Application

Figure 24. Global Biosimilars and Innovative Biological Drugs Sales Market Share by Application (2019-2024)

Figure 25. Global Biosimilars and Innovative Biological Drugs Sales Market Share by Application in 2023

Figure 26. Global Biosimilars and Innovative Biological Drugs Market Share by Application (2019-2024)

Figure 27. Global Biosimilars and Innovative Biological Drugs Market Share by Application in 2023

Figure 28. Global Biosimilars and Innovative Biological Drugs Sales Growth Rate by Application (2019-2024)

Figure 29. Global Biosimilars and Innovative Biological Drugs Sales Market Share by Region (2019-2024)

Figure 30. North America Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 31. North America Biosimilars and Innovative Biological Drugs Sales Market Share by Country in 2023

Figure 32. U.S. Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 33. Canada Biosimilars and Innovative Biological Drugs Sales (K MT) and Growth Rate (2019-2024)

Figure 34. Mexico Biosimilars and Innovative Biological Drugs Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 36. Europe Biosimilars and Innovative Biological Drugs Sales Market Share by Country in 2023

Figure 37. Germany Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 38. France Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 39. U.K. Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 40. Italy Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 41. Russia Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 42. Asia Pacific Biosimilars and Innovative Biological Drugs Sales and Growth Rate (K MT)

Figure 43. Asia Pacific Biosimilars and Innovative Biological Drugs Sales Market Share by Region in 2023

Figure 44. China Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 45. Japan Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 46. South Korea Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 47. India Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 48. Southeast Asia Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 49. South America Biosimilars and Innovative Biological Drugs Sales and Growth Rate (K MT)

Figure 50. South America Biosimilars and Innovative Biological Drugs Sales Market Share by Country in 2023

Figure 51. Brazil Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 52. Argentina Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 53. Columbia Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 54. Middle East and Africa Biosimilars and Innovative Biological Drugs Sales and Growth Rate (K MT)

Figure 55. Middle East and Africa Biosimilars and Innovative Biological Drugs Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 57. UAE Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 58. Egypt Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 59. Nigeria Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 60. South Africa Biosimilars and Innovative Biological Drugs Sales and Growth Rate (2019-2024) & (K MT)

Figure 61. Global Biosimilars and Innovative Biological Drugs Production Market Share by Region (2019-2024)

Figure 62. North America Biosimilars and Innovative Biological Drugs Production (K MT)

Growth Rate (2019-2024)

Figure 63. Europe Biosimilars and Innovative Biological Drugs Production (K MT)

Growth Rate (2019-2024)

Figure 64. Japan Biosimilars and Innovative Biological Drugs Production (K MT) Growth Rate (2019-2024)

Figure 65. China Biosimilars and Innovative Biological Drugs Production (K MT) Growth Rate (2019-2024)

Figure 66. Global Biosimilars and Innovative Biological Drugs Sales Forecast by Volume (2019-2032) & (K MT)

Figure 67. Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Biosimilars and Innovative Biological Drugs Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Biosimilars and Innovative Biological Drugs Market Share Forecast by Type (2025-2032)

Figure 70. Global Biosimilars and Innovative Biological Drugs Sales Forecast by Application (2025-2032)

Figure 71. Global Biosimilars and Innovative Biological Drugs Market Share Forecast by Application (2025-2032)

I would like to order

Product name: Global Biosimilars and Innovative Biological Drugs Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/GCCACE01D28FEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCCACE01D28FEN.html>